MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) will have its CEO, Michael Castagna, PharmD, participate in a Fireside Chat at the 2021 SVB Leerink Global Healthcare Conference on February 25, 2021, at 1:00 pm (ET). Interested individuals can access the webcast through the Company's website, with a replay available for 14 days post-event. MannKind is known for developing inhaled therapeutic products, including Afrezza® (insulin human) Inhalation Powder, the only FDA-approved inhaled ultra rapid-acting mealtime insulin in the U.S.

WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:00 pm (ET). Interested parties can access a link to the webcast from the Events & Presentations section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
818-661-5000
ir@mannkindcorp.com

FAQ

When is MannKind's CEO speaking at the SVB Leerink Global Healthcare Conference?

MannKind's CEO, Michael Castagna, will speak at the SVB Leerink Global Healthcare Conference on February 25, 2021, at 1:00 pm (ET).

How can I access the MannKind conference presentation?

You can access the MannKind conference presentation via a link in the Events & Presentations section of their website.

What is Afrezza and its significance for MannKind?

Afrezza® is MannKind's first FDA-approved product, being the only inhaled ultra rapid-acting mealtime insulin available in the United States.

What makes MannKind Corporation unique in its product offerings?

MannKind focuses on developing inhaled therapeutic products specifically for patients with endocrine and orphan lung diseases.

Where is MannKind Corporation headquartered?

MannKind Corporation is headquartered in Westlake Village, California.